As previously reported, Cantor Fitzgerald initiated coverage of InflaRx (IFRX) with an Overweight rating and $10 price target Upcoming Phase 3 interim data due in May for the company’s lead asset vilobelimab in pyoderma gangrenosum is a “potentially major, unappreciated catalyst,” the analyst tells investors. The risk/reward into this blinded interim analysis has a “very large positive skew,” the analyst argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx initiated with an Overweight at Cantor Fitzgerald
- InflaRx Approves Key Resolutions at Annual Shareholder Meeting
- InflaRx N.V. Announces 2025 Annual General Meeting Agenda
- InflaRx’s Promising Drug Pipeline and Market Potential Drive Buy Rating
- InflaRx price target raised to $10 from $7 at Guggenheim